Suggests empiric vitamin D supplementation plus lifestyle modification to reduce diabetes progression risk in adults with high-risk prediabetes. Use when a clinician considers vitamin D for patients with prediabetes meeting 2 or more ADA glycemic criteria (fasting glucose, HbA1c, 2‑hour OGTT) to prevent diabetes.
Installs into .claude/skills of the current project.
Are you the author of Endo Vit D Supp High Risk Prediabetes?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-vit-d-supp-high-risk-prediabetes)
---
name: endo-vit-d-supp-high-risk-prediabetes
description: Suggests empiric vitamin D supplementation plus lifestyle modification to reduce diabetes progression risk in adults with high-risk prediabetes. Use when a clinician considers vitamin D for patients with prediabetes meeting 2 or more ADA glycemic criteria (fasting glucose, HbA1c, 2‑hour OGTT) to prevent diabetes.
---
# Vitamin D supplementation for high-risk prediabetes
## STEP 1 — Gather Information
Assess glycemic status using ADA criteria: fasting plasma glucose 100‑125 mg/dL, HbA1c 5.7‑6.4%, 2‑hour plasma glucose 140‑199 mg/dL after 75‑g OGTT. Count how many of these three criteria are met. Also verify that lifestyle modification (diet, physical activity, weight loss) is being implemented or planned.
## STEP 2 — Rule In / Rule Out
**Rule in** high‑risk prediabetes if the patient meets **≥2** of the ADA glycemic criteria (or has documented impaired glucose tolerance).
**Rule out** if 0‑1 criteria are met (low‑risk prediabetes) or glucose values are normal; empiric vitamin D supplementation is not recommended for diabetes prevention in this group.
## STEP 3 — Classify or Stratify
If high‑risk prediabetes is confirmed, no further stratification by 25(OH)D level is required per guideline; the recommendation applies regardless of baseline vitamin D status. Proceed to decide on supplementation.
## STEP 4 — Decide
Initiate empiric vitamin D supplementation (dose not specified; trials used 842‑7543 IU daily, weighted average ≈3500 IU/day) **in addition to** continuing lifestyle modification. Re‑evaluate glycemic status periodically per usual prediabetes care.
## Clinical Guardrails / Mimics / Pitfalls
- Do **not** rely on serum 25(OH)D testing to guide or withhold supplementation in this population.
- Avoid high‑dose intermittent bolus regimens without monitoring for hypercalcemia or nephrolithiasis.
- Do **not** use in patients with established indications for vitamin D treatment (e.g., hypocalcemia, renal osteodystrophy) unless those indications are also present.
- Do **not** substitute vitamin D for lifestyle modification; it is adjunctive only.
- Do **not** extrapolate to pregnant individuals, children, or adults ≥75 years without separate indication.
## Concrete Clinical Example
A 58‑year‑old man with BMI 31 kg/m² has fasting glucose 112 mg/dL and HbA1c 6.0% (2 ADA criteria met); 2‑hour OGTT is 130 mg/dL. He has been advised on diet and exercise. **Decision:** Start empiric vitamin D supplementation (e.g., 2000‑3000 IU daily) and reinforce lifestyle modification.
**Source:** Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2024, DOI: 10.1210/clinem/dgae290